犀角散加味干预HBV相关慢加急性肝衰竭的前期临床研究  

Clinical trial of Supplemented Xijiao Powder treating HBV associated prior acute-on-chronic liver failure

作　　者：尹燕耀[1] 林云华[1] 邵发助 林晖明[1] 宗亚力[1] 万勇[1] 

机构地区：[1]南昌市第九医院,江西南昌330002 [2]都昌县中医院,江西九江332600

出　　处：《中成药》2017年第8期1591-1594,共4页Chinese Traditional Patent Medicine

基　　金：国家临床重点专科建设项目经费资助(国卫医发[2013]42号);2014年江西省科技计划项目(20141BDH80031);2014南昌市指导性科技计划项目(洪科发计字[2014]197号第35项)

摘　　要：目的探讨犀角散加味(水牛角、黄连、升麻,等)对HBV相关慢加急性肝衰竭前期的临床疗效观察。方法收集给予西医内科综合治疗75例HBV相关慢加急性肝衰竭前期患者,分为试验组与对照组,试验组在对照组基础上予犀角散加味口服,治疗1个月,观察患者症状和体征,测定丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、白蛋白(ALB)、胆碱酯酶(CHE)、凝血酶原活动度(PTA)水平,统计患者肝衰竭的发生率。结果犀角散加味治疗HBV慢加急性肝衰竭前期患者能够改善部分症状、体征,提高PTA水平,降低肝衰竭发生率,其他指标同期比较无明显差异。结论犀角散加味对HBV相关慢加急性肝衰竭前期有一定治疗作用,可能与早期阻断肝衰竭发生有关。AIM To observe the clinical role for Supplemented Xijiao Powder（ Bubali cornu,Coptidis Rhizoma,Cimicifugae Rhizoma,etc.） in management of hepatitis B virus（ HBV） associated acute-on-chronic liver failure. METHOD Seventy-five patients,including the ones receiving internal medicine treatment,were divided into control group and experimental group. The experimental group received conventional treatment and additionally took Supplemented Xijiao Powder for one month. The clinical symptoms and signs were observed. Levels of ALT,AST,TBIL,ALB,CHE,PTA were measured,and the incidence of liver failure was evaluated. RESULTS Supplemented Xijiao Powder could improve symptoms,signs and the level of PTA. The incidence of liver failure tended to reduce. The comparison of other indexes had no marked difference. CONCLUSION Supplemented Xijiao Powder has a certain therapeutic effect on HBV associated prioracute-on-chronic liver failure. Its mechanism may be related to blocking the occurrence of liver failure.

关 键 词：犀角散加味 HBV(乙型肝炎病毒) 慢加急性肝衰竭前期 临床研究 

分 类 号：R287[医药卫生—中药学]